Sandbox Reserved 1709

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 31: Line 31:
[[Image:Catalytic Mech Pic.png |350 px| right| thumb]]
[[Image:Catalytic Mech Pic.png |350 px| right| thumb]]
-
The catalytic mechanism of VKOR is highly regulated and uses reactive catalytic cysteines to activate Vitamin K TO INSERT PRECISE CHEMICAL TERMS. The enzyme begins in <scene name='90/906893/Stage_1_catalytic_cycle/1'>stage I</scene> in the open conformation with the cap domain open to allow substrate binding. Once a substrate binds, the cap domain transitions to the closed conformation. VKOR is now in <scene name='90/906893/Stage_2_catalytic_cycle/1'>stage II</scene>. To stabilize the substrate bound closed conformation, the cap domain helps initiate a catalytic reaction of cysteines to break the disulfide bridge that was stabilizing stage 1. Free cysteines are now available that provide strong stabilization of the closed conformation through interactions with the cap domain and the bound substrate. This puts the enzyme in <scene name='90/904314/Stage_3_catalytic_cycle/2'> stage III</scene>, where the catalytic free cysteines react to form a new disulfide bridge, releasing the activated product into the blood stream to promote anticoagulation. With two stable disulfide bridges and VKOR unbound, the enzyme is now in its final, unreactive <scene name='90/904314/Stage_4_catalytic_cycle/4'> stage IV</scene>. VKOR must undergo conformational changes to return to Stage 1 and restart the catalytic process to activate Vitamin K again.
+
The catalytic mechanism of VKOR is highly regulated and uses reactive catalytic cysteines to activate Vitamin K to promote blood coagulation throughout the cardiovascular system. The enzyme begins in <scene name='90/906893/Stage_1_catalytic_cycle/1'>stage I</scene> in the open conformation with the cap domain open to allow substrate binding. Once a substrate binds, the cap domain transitions to the closed conformation when the C51-C132 disulfide bridge is attacked by reactive C43 located within the cap domain. This reaction forms a new disulfide bridge between C43 and C51 that pulls the cap domain over the binding pocket with the substrate bound to stabilize the closed conformation of VKOR, as illustrated in Figure 2. VKOR is now in <scene name='90/906893/Stage_2_catalytic_cycle/1'>stage II</scene>. Free cysteines are now available that provide strong stabilization of the closed conformation through interactions with the cap domain and the bound substrate. This puts the enzyme in <scene name='90/904314/Stage_3_catalytic_cycle/2'> stage III</scene>, where a free C135 is purposed to interact with the substrate within the binding pocket to stabilize it during activation. The catalytic free C132 located between the cap domain and helical tunnel is very reactive and will attack this C135 to break that interaction with the substrate and release the activated Vitamin K product into the blood stream to promote coagulation. Two very stable disulfide bridges between C43-C41 and C132-C135 are now present and VKOR is unbound, so the enzyme is in its final, unreactive <scene name='90/904314/Stage_4_catalytic_cycle/4'> stage IV</scene>. VKOR must undergo conformational changes to return to Stage 1 and reactivate its catalytic cysteines so that another molecule of Vitamin K can bind and be activated.
== Disease and Treatment ==
== Disease and Treatment ==

Revision as of 14:15, 12 April 2022

VKOR with KO bound.

Drag the structure with the mouse to rotate

References

1. Elshaikh, A. O., Shah, L., Joy Mathew, C., Lee, R., Jose, M. T., & Cancarevic, I. "Influence of Vitamin K on Bone Mineral Density and Osteoporosis" (2020) Cureus, 12(10), e10816. [1]

2. Guomin Shen, Weidong Cui, Qing Cao, Meng Gao, Hongli Liu, Gaigai Su, Michael L. Gross, Weikai Li. The catalytic mechanism of vitamin K epoxide reduction in a cellular environment. (2021) Journal of Biological Chemistry, Volume 296,100145. https://doi.org/10.1074/jbc.RA120.015401.

3. Li, Weikai et al. “Structure of a bacterial homologue of vitamin K epoxide reductase.” Nature vol. 463,7280 (2010): 507-12. doi:10.1038/nature08720.

4. Liu S, Li S, Shen G, Sukumar N, Krezel AM, Li W. Structural basis of antagonizing the vitamin K catalytic cycle for anticoagulation. Science. 2021 Jan 1;371(6524):eabc5667. doi: 10.1126/science.abc5667. Epub 2020 Nov 5. PMID: 33154105; PMCID: PMC7946407.

5. Yang W., et. al. “VKORC1 Haplotypes Are Associated With Arterial Vascular Diseases (Stroke, Coronary Heart Disease, and Aortic Dissection)” (2006) Circulation. ;113:1615–1621 [2]


Personal tools